Prognostic Value and Outcome for ETV6/RUNX1-Positive Pediatric Acute Lymphoblastic Leukemia: A Report From the South China Children's Leukemia Group - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34988026/
doi: 10.3389/fonc.2021.797194. 1 Children's Medical Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China. 2 Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Sun Yat-Sen Memorial...
Conclusions: ETV6/RUNX1-positive pediatric ALL showed an excellent outcome but lack of independent prognostic significance in South China. However, for older patients who have the ETV6/RUNX1 fusion and slow response to therapy, to opt for more intensive treatment.
Impact of High Disease Burden on Survival in Pediatric Patients with B-ALL Treated with Tisagenlecleucel - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34875402/
1 The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland. 2 Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, Tennessee. 3 The Sidney Kimmel...
Conclusions: Tisagenlecleucel induced high initial response rates in a contemporary cohort of pediatric and AYA patients with B-ALL. However, 48% of patients experienced subsequent disease relapse, including 6 with antigen-escape variants. This highlights a considerable limitation of single-agent autologous CD19-CAR T-cell therapy. Pretreatment...
Evaluation of CD30 expression in B ALL and its correlation with MRD(Minimum Residual Disease) - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34899928/
doi: 10.4103/jrms.JRMS_1024_20. 1 Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Free PMC article Amirhossein Kazemian et al. J Res Med Sci. Free PMC article...
Conclusion: Lower MRD on day 28 after chemotherapy was seen in B-ALL patients with baseline CD30 expression.
Characterization of Extramedullary Disease in B-ALL and Response to CAR T-cell Therapy - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34920453/
Chimeric antigen receptor (CAR) T-cells effectively eradicate medullary B-cell acute lymphoblastic leukemia (B-ALL) and can traffic to and clear central nervous system (CNS) involvement. CAR T-cell activity in non¬contral nervous...
Conclusions: CAR T-cells are active in B-ALL non-CNS EMD. Still, non-CNS EMD response to CAR T-cells may be delayed and sub-optimal, particularly with multifocal disease. Serial FDG PET-CT scans are necessary for identifying and monitoring non-CNS EMD.
Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34916387/
1 Department of Hematology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. 2 Department of Immunopathology, Post Graduate Institute of Medical Education and Research, Chandigarh, India. 3 Department...
Conclusion: We have demonstrated the impact of MRD testing in MM using MFC with a long follow-up data, suggesting its routine incorporation in monitoring the disease independent of the immunofixation status.